Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes (City of Hope Medical Center)

N/A

Report date: 2022/12/31 18:10:07

Base Information

Drug NameAutologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes (City of Hope Medical Center)

Drug Alias NameAutologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-cells (City of Hope Medical CenterAutologous Anti-PSCA(dCH2)BBz-CAR T-cells ((City of Hope Medical Center)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-PSCA

TargetsProstate stem cell antigen

Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesCity Of Hope National Medical Center

China Registration ClassN/A

Develop Information

Active CompaniesCity Of Hope National Medical Center

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A